DOCSLIB.ORG

Scratching Behavior in Mice Associated with Ige-Mediated Allergic Cutaneous Reaction and Its Pharmacological Characterization

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Scratching Behavior in Mice Associated with Ige-Mediated Allergic Cutaneous Reaction and Its Pharmacological Characterization Allergology International (1997) 46: 117-124 Original Article Scratching behavior in mice associated with IgE-mediated allergic cutaneous reaction and its pharmacological characterization Keiichi Musoh, Nobuaki Nakamura, Toshimi Sakurai, Naoki Inagaki and Hiroichi Nagai Department of Pharmacology, Gifu Pharmaceutical University,Gifu, Japan ABSTRACT mediated allergic cutaneous reaction and that the reaction is pharmacologically similar, but not identical, Scratching behavior observed after epicutaneous to that caused by 48/80. Although histamine is challenge with the antigen 2,4-dinitrofluorobenzene considered to participate in the formation of ear (DNFB) in the ear of BALB/c mice passively sensitized edema, it may not play an important role in the with anti-dinitrophenol (DNP). Immunoglobulin (Ig) E generation of scratching. was characterized pharmacologically and compared with that caused by compound 48/80. Although DNFB Key words: antihistamine, compound 48/80, application itself caused scratching behavior in non- cyproheptadine, dinitrofluorobenzene, IgE-mediated sensitized mice, the number of scratchings apparently allergic cutaneous reaction, prednisolone, scratching increased in sensitized mice from 60min after antigen behavior. application in comparison with non-sensitized control mice. Prednisolone, cyproheptadine, dibucaine and naloxone significantly inhibited the DNFB-induced INTRODUCTION scratching behavior, whereas the histamine H1- The itch is a sensation associated with a strong desire to receptor antagonists HSR-609, cetirizine and scratch. In many diseases, such as allergic dermatitis, terfenadine only showed a tendency to inhibit chronic renal failure, hepatic cholestasis and diabetes scratching. Injection of 48/80 into the rostral part of mellitus, pruritus is one of the most important the back also caused scratching. The first scratching symptoms.1-4Particularly in skin diseases, pruritus with an was observed within 10min after injection and lasted extremely unpleasant sensation is the most significant intermittently for 30min. The 48/80-induced problem, but the mechanisms causing itching remain to scratching was markedly inhibited by cyproheptadine, be elucidated. It is necessary, therefore, to clarify the dibucaine and naloxone, but not by prednisolone and physiological and pathological mechanisms of pruritus. the histamine H1-receptor antagonists. Ear edema At present, however, no established animal model is caused by DNFB application in sensitized mice was available, because of the difficultiesin behavioral animal markedly inhibited by prednisolone, HSR-609, experiments, to investigate pruritus. Clinically, scratch is cetirizine, terfenadine and cyproheptadine, whereas used as an objective measure of itch. In 1995, Kuraishi et dibucaine and naloxone failed to affect ear edema. al.5 reported that scratching in mice caused rostral back These results indicate that scratching behavior could injection of the pruritogenic agents compound 48/80 be induced in mice in association with an IgE- (48/80) and substance P may be due to itch, but not pain. They also indicated that histamine and algesiogenic Correspondence: Dr Hiroichi Nagai, Department of agents, capsaicin and formalin, were without significant Pharmacology, Gifu Pharmaceutical University, 5-6-1 effects. Mitahorahigashi, Gifu 502, Japan. Email: ＜[email protected]＞ In contrast, application of 2,4-dinitrofluorobenzene Received 12 September 1996. Accepted for publication 21 (DNFB), a typical contact sensitizer, on the ear of mice February 1997. sensitized with anti-dinitrophenol (DNP) IgE causes 118 K MUSOH ET AL. biphasic ear edema.6-9 The immediate phase edema Chemical Co.), cyproheptadine hydrochloride (Nacalai peaked 1h after DNFB application, is transient and is Tesque), dibucaine hydrochloride (Nacalai Tesque) and considered to be generated by mast cell mediators, such compound 48/80 (Sigma Chemical Co.) were dissolved as histamine and serotonin.9 The late phase edema is in physiological saline. Prednisolone acetate (Shionogi long-lasting and shows a peak 24h after antigen Pharmaceutical Co. Ltd, Osaka, Japan) was also application. Pro-inflammatory cytokines, such as tumor suspended in physiological saline. HSR-609, cetirizine, necrosis factor-α and interleukin-1β, are suggested to be terfenadine and cyproheptadine were administered orally involved in the late-phase edema.8-10 to mice 1h prior to the elicitation of any reaction. In the present study, the scratching behavior caused by Naloxone was given intravenously 1h before the an allergic cutaneous reaction in mice was investigated reaction. Prednisolone was injected intraperitoneally 2h according to the method reported by Kuraishi et al.5 and before the reaction. Dibucaine was given to mice attempts were made to pharmacologically characterize subcutaneously at the time of stimulation. the scratching behavior. DNFB-induced scratching behavior METHODS 2,4-Dinitrofluorobenzene treatment in sensitized mice Animals was performed as reported previously8-10 with a slight modification. Briefly, mice received an intravenous Female BALB/c mice, 8-9 weeks old, purchased from injection of 1.0mL monoclonal IgE preparation. Twenty- Japan SLC (Hamamatsu, Japan) were used throughout. four hours after passive sensitization, DNFB acetone- olive oil solution was applied to both sides of the ears. Antigen Although we have observed mouse biphasic cutaneous 2,4-Dinitrofluorobenzene, purchased from Nacalai reactions after applying 25μL of a 0.15% DNFB Tesque (Kyoto, Japan), was used as an antigen; it was solution, a high incidence of scratching was observed dissolved in a mixture of acetone and olive oil (3:1). even in non-sensitized mice under such experimental conditions. We therefore painted 5uL of a 0.75% DNFB Monoclonal IgE solution on both sides of the ear to reduce non-specific scratching when examining scratching behavior. Mouse monoclonal IgE against DNP residue was Immediately after antigen application, mice were put into prepared by culturing a cell line, ECl, as previously acrylic cages (30×30×12cm) and their behavior was reported.8 The culture supernatant of ECl was stored at observed. Instances of scratching of the ear lobes by the -80℃ and was used as a source of IgE. The maximum hind paws were counted. The mice showed several dilution of the IgE preparation to give a positive scratchings for approximately 1s and a series of these cutaneous anaphylaxis in Wistar rats challenged with behaviors was counted as one incident of scratching DNP-conjugated bovine serum albumin was 1:1024. according to the method described by Kuraishi et al.5 The IgE content of the preparation, estimated by enzyme- linked immunosorbent assay, was 1415ng/mL. 48/80-induced scratching behavior Drugs 48/80 solution in a volume of 100μL wos injected subcutaneously into the rostral part of the back of mice.5 3-[4-(8-Fluoro-5,11-dihydro [1] benzoxepino [4,3-b] Immediately after injection of 48/80, mice were put into pyridin-11-ylidene) piperidino] propionic acid (HSR- acrylic cages and scratching behaviors were counted as 609), a novel amphoteric antiallergic agent with a potent mentioned above. and long-lasting histamine H,-receptor antagonistic property,11 and cetirizine dihydrochloride12,13 were DNFB-induced edematous reaction synthesized by Hokuriku Seiyaku Co. Ltd (Fukui, Japan). Terfenadine14was purchased from Sigma Chemical Co. An IgE-dependent cutaneous reaction was performed in (St Louis, MO, USA).These agents were suspended in 5% the mouse ear as reported previously.8-10 The ear edema arabic gum solution. Naloxone hydrochloride (Sigma caused by the application of DNFB was evaluated by SCRATCHING BEHAVIOR IN MICE 119 measuring the ear thickness by a micrometer (Peacock 48/80-induced scratching in mice Upright Dial Gauge, Ozaki, Tokyo, Japan) before and 1 When BALB/c mice received an injection of 48/80 at h after antigen challenge. doses of 10 and 100μg into the rostral part of the back, they exhibited scratching of or around the injected site by Statistics the hind paws. The first scratching behavior appeared Data are expressed as the mean±SEM. Statistical within 10min after injection and lasted intermittently for comparisons were made by parametric Duncan's 30min. 48/80 at 100μg was effective in causing multiple range test, using the computer software YUKMS scratching, but was less effective at 10μg. A dose of 1 (version 5.0; Kanagawa, Japan) and P<0.05 was taken μg 48/80 failed to induce scratching (Fig. 2a). The to indicate significance. incidence of scratching caused by 100μg 48/80 peaked between 10 and 15min. As we had confirmed in RESULTS preliminary experiments that the incidence of 48/80- induced scratching was low later than 45min after its DNFB-induced scratching behavior in injection (data not shown), mouse behavior was only sensitized mice observed for 45min after injection of 48/80 in the pre- Figure 1a shows the results of a time course study of sent experiments. In the following experiments, scratching scratching behavior for 120min after DNFB or vehicle behaviorwas caused by injecting 100μg 48/80. application to the ears of sensitized or intact mice. Results of administration of prednisolone are shown in Scratching behavior was caused by DNFB application Fig. 2b. Prednisolone failed to affect 48/80-induced itself in intact mice in comparison with vehicle-treated scratching behavior in mice. controls. The number of scratchings, however, As shown in Fig. 2c-e, HSR-609, cetirizine and significantly
Load more

Recommended publications
  • Prescribing Information for High-Dose Fexofenadine in the Management of Urticaria in Adults
    1 Prescribing information for high-dose fexofenadine in the management of urticaria in adults This prescribing information document outlines the prescribing responsibilities between the specialist and GP. GPs are invited to participate. If the GP feels that such prescribing is outside their area of expertise or have clinical concerns about the safe management of the drug in primary care, then he or she is under no obligation to do so. In such an event, clinical responsibility for the patient’s health remains with the specialist. If a specialist asks the GP to prescribe, the GP should reply to this request as soon as practicable. Consultant details GP details Patient details Name: Name: Name: Address: Address: NHS Number: Email: Email: Date of birth: Contact number: Contact number: Contact: Introduction Fexofenadine is a second generation non-sedating H1-antihistamine used in the treatment of allergic disorders. Fexofenadine is a pharmacologically active metabolite of terfenadine. Licensed indication: In adults and children 12 years and older, the licensed dose is 180mg daily for the relief of symptoms associated with chronic idiopathic urticaria. Unlicensed indication (the focus of this document): As advised by Europeani and British Association of Dermatologistsii guidelines, doses of antihistamines up to four times the recommended daily dose may be used in the treatment of urticaria. Adult dosage and administration The licensed maximum recommended daily dose is 180mg once daily taken before a meal. Doses of up to four times the daily recommended dose have been used in the treatment of severe urticaria (unlicensed indication)i Available as: 30mg, 120mg and 180mg tablets Specialist responsibilities Provide patient/carer with relevant written information on the unlicensed use of high-dose fexofenadine and possible side-effects.
    [Show full text]
  • Profile Profile Profile Profile Uses and Administration Adverse Effects And
    640 Antihistamines Propiomazine Hydrochloride {BANM, r!NNMJ P..r�p�rc:Jti()n.� ............................ m (details are given in Volume B) propiorf,azina; to o azine; Chiorhydrate ProprietaryPreparations HidrodoruroPropi<;>rn deazini HydrochloridP pium; f1ponvtot,la3Y!Ha China: Qi Qi Hung. : de; Single-ingredient Preparafions. Loderixt. CIH'f); rMAPOX!10p!'\A. C;cJcl1_,--N_,QS,HCI�3.76_91 Rupatadine is an antihistamine with platelet-activating CAS 240) 5-9. factor (PAF) antagonist activity that is used for the Terfenadine (BAN, USAN, r!NN) treatment of allergic rhinitis (p. 612.1) and chronic 1 idiopathic urticaria (p. 612.3). It is given as the fumarate although doses are expressed in terms of the base; rupatadine fumarate 12.8 mg is equivalent to about 10 mg of rupatadine. The usual oral dose is the equivalent of 10 mg once daily of rupatadine. Izquierdo I. et a!. Rupatadine: a new selective histamine HI receptor and platelet-activating factor (PAF) antagonist: a review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today 2003; 39: 451-68. 2. Kearn SJ,Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs 2007; 67: 457-74. 3. Fantin et at. International Rupatadine study group. A 12-week 5, 8: (Terfenadine). A white or almost white, placebo-controlled study of rupatadine 10 mg once daily compared with Ph. Bur. cetirizine IO mg once daily, in the treatment of persistent allergic crystalline powder. It shows polymorphism. Very slightly rhinitis. Allergy 2008; 63: 924-3 1. soluble in water and in dilute hydrochloric acid; freely 4.
    [Show full text]
  • Antihistamines in the Treatment of Chronic Urticaria I Jáuregui,1 M Ferrer,2 J Montoro,3 I Dávila,4 J Bartra,5 a Del Cuvillo,6 J Mullol,7 J Sastre,8 a Valero5
    Antihistamines in the treatment of chronic urticaria I Jáuregui,1 M Ferrer,2 J Montoro,3 I Dávila,4 J Bartra,5 A del Cuvillo,6 J Mullol,7 J Sastre,8 A Valero5 1 Service of Allergy, Hospital de Basurto, Bilbao, Spain 2 Department of Allergology, Clínica Universitaria de Navarra, Pamplona, Spain 3 Allergy Unit, Hospital La Plana, Villarreal (Castellón), Spain 4 Service of Immunoallergy, Hospital Clínico, Salamanca, Spain 5 Allergy Unit, Service of Pneumology and Respiratory Allergy, Hospital Clínic (ICT), Barcelona, Spain 6 Clínica Dr. Lobatón, Cádiz, Spain 7 Rhinology Unit, ENT Service (ICEMEQ), Hospital Clínic, Barcelona, Spain 8 Service of Allergy, Fundación Jiménez Díaz, Madrid, Spain ■ Summary Chronic urticaria is highly prevalent in the general population, and while there are multiple treatments for the disorder, the results obtained are not completely satisfactory. The second-generation H1 antihistamines remain the symptomatic treatment option of choice. Depending on the different pharmacokinetics and H1 receptor affi nity of each drug substance, different concentrations in skin can be expected, together with different effi cacy in relation to the histamine-induced wheal inhibition test - though this does not necessarily have repercussions upon clinical response. The antiinfl ammatory properties of the H1 antihistamines could be of relevance in chronic urticaria, though it is not clear to what degree they infl uence the fi nal therapeutic result. Before moving on to another therapeutic level, the advisability of antihistamine dose escalation should be considered, involving increments even above those approved in the Summary of Product Characteristics. Physical urticaria, when manifesting isolatedly, tends to respond well to H1 antihistamines, with the exception of genuine solar urticaria and delayed pressure urticaria.
    [Show full text]
  • Antihistamine Therapy in Allergic Rhinitis
    CLINICAL REVIEW Antihistamine Therapy in Allergic Rhinitis Paul R. Tarnasky, MD, and Paul P. Van Arsdel, Jr, MD Seattle, Washington Allergic rhinitis is a common disorder that is associated with a high incidence of mor­ bidity and considerable costs. The symptoms of allergic rhinitis are primarily depen­ dent upon the tissue effects of histamine. Antihistamines are the mainstay of therapy for allergic rhinitis. Recently, a second generation of antihistamines has become available. These agents lack the adverse effect of sedation, which is commonly associated with older antihistamines. Current practice of antihistamine therapy in allergic rhinitis often involves random selection among the various agents. Based upon the available clinical trials, chlorpheniramine appears to be the most reasonable initial antihistaminic agent. A nonsedating antihis­ tamine should be used initially if a patient is involved in activities where drowsiness is dangerous. In this comprehensive review of allergic rhinitis and its treatment, the cur­ rent as well as future options in antihistamine pharmacotherapy are emphasized. J Fam Pract 1990; 30:71-80. llergic rhinitis is a common condition afflicting some­ defined by the period of exposure to those agents to which A where between 15 and 30 million people in the United a patient is sensitive. Allergens in seasonal allergic rhinitis States.1-3 The prevalence of disease among adolescents is consist of pollens from nonflowering plants such as trees, estimated to be 20% to 30%. Two thirds of the adult grasses, and weeds. These pollens generally create symp­ allergic rhinitis patients are under 30 years of age.4-6 Con­ toms in early spring, late spring through early summer, sequently, considerable costs are incurred in days lost and fall, respectively.
    [Show full text]
  • Inhibitory Effect of Terfenadine, a Selective H1 Histamine Antagonist, on Alcoholic Beverage-Induced Bronchoconstriction in Asthmatic Patients
    Eur Respir J, 1995, 8, 619–623 Copyright ERS Journals Ltd 1995 DOI: 10.1183/09031936.95.08040619 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 Inhibitory effect of terfenadine, a selective H1 histamine antagonist, on alcoholic beverage-induced bronchoconstriction in asthmatic patients S. Myou*, M. Fujimura**, K. Nishi*, T. Ohka*, T. Matsuda** Inhibitory effect of terfenadine, a selective H1 histamine antagonist, on alcoholic bever- *Division of Respiratory Medicine, Ishikawa age-induced bronchoconstriction in asthmatic patients. S. Myou, M. Fujimura, K. Nishi, Prefectural Central Hospital, Kanazawa, T. Ohka, T. Matsuda. ERS Journals Ltd 1995. Japan. **The Third Dept of Internal Medicine, Kanazawa University School of ABSTRACT: We wanted to evaluate the effect of terfenadine, a selective H1-recep- tor antagonist, on alcoholic beverage-induced bronchoconstriction. Medicine, Kanazawa, Japan. Eight patients with alcohol-induced asthma received terfenadine (60 mg, twice on Correspondence: S. Myou the test day) or placebo, with the last dosing 2 h before the test in a double-blind, The Third Dept of Internal Medicine randomized, cross-over manner. On two separate study days, each subject drank Kanazawa University School of Medicine the same brand and volume of alcoholic beverage (beer or Japanese saké), and bron- 13-1 Takara-machi choconstriction was assessed as change in peak expiratory flow (PEF) over 120 min Kanazawa 920 postchallenge. Inhalation challenges were performed with the same alcoholic bev- Japan erage with which they had been orally challenged. Keywords: Alcohol The mean (SEM) percentage fall in PEF 15, 30, 45, 60, 90 and 120 min after the oral alcohol challenge was significantly reduced from 12.0 (3.1), 17.0 (1.7), 15.8 (2.3), asthma histamine 15.2 (3.4), 16.6 (4.8) and 14.7 (5.2) %, to 2.6 (1.8), 2.1 (1.6), 3.9 (1.2), 5.7 (2.2), 6.5 terfenadine (2.6), 5.1 (1.6) %, respectively, by terfenadine.
    [Show full text]
  • Histamine and Antihistamines Sites of Action Conditions Which Cause Release Aron H
    Learning Objectives I Histamine Pharmacological effects Histamine and Antihistamines Sites of action Conditions which cause release Aron H. Lichtman, Ph.D. Diagnostic uses Associate Professor II Antihistamines acting at the H1 and H2 receptor Pharmacology and Toxicology Pharmacological effects Mechanisms of action Therapeutic uses Side effects and drug interactions Be familiar with the existence of the H3 receptor III Be able to describe the main mechanism of action of cromolyn sodium and its clinical uses Histamine Pharmacology First autacoid to be discovered. (Greek: autos=self; Histamine Formation akos=cure) Synthesized in 1907 Synthesized in mammalian tissues by Demonstrated to be a natural constituent of decarboxylation of the amino acid l-histidine mammalian tissues (1927) Involved in inflammatory and anaphylactic reactions. Local application causes swelling redness, and edema, mimicking a mild inflammatory reaction. Large systemic doses leads to profound vascular changes similar to those seen after shock or anaphylactic origin Histamine Stored in complex with: Heparin Chondroitin Sulfate Eosinophilic Chemotactic Factor Neutrophilic Chemotactic Factor Proteases 1 Conditions That Release Histamine 1. Tissue injury: Any physical or chemical agent that injures tissue, skin or mucosa are particularly sensitive to injury and will cause the immediate release of histamine from mast cells. 2. Allergic reactions: exposure of an antigen to a previously sensitized (exposed) subject can immediately trigger allergic reactions. If sensitized by IgE antibodies attached to their surface membranes will degranulate when exposed to the appropriate antigen and release histamine, ATP and other mediators. 3. Drugs and other foreign compounds: morphine, dextran, antimalarial drugs, dyes, antibiotic bases, alkaloids, amides, quaternary ammonium compounds, enzymes (phospholipase C).
    [Show full text]
  • Clomipramine 25 Mg Capsules, Hard
    Package leaflet: Information for the patient Other medicines and Clomipramine Tell your doctor if you are taking, have recently Clomipramine 10 mg Capsules, Hard taken or might take any other medicines. Clomipramine 25 mg Capsules, Hard Some medicines may increase the side effects of Clomipramine 50 mg Capsules, Hard Clomipramine and may sometimes cause very clomipramine hydrochloride serious reactions. Do not take any other medicines whilst taking Clomipramine without first talking to Read all of this leaflet carefully before you your doctor, especially: start taking this medicine because it contains - medicines for depression, particularly MAOIs (see important information for you. section “Do not take” above) e.g. tranylcypromine, - Keep this leaflet. You may need to read it again. phenelzine, moclobemide; SSRIs e.g. fluoxetine (or - If you have any further questions, ask your have taken within the last 3 weeks), fluvoxamine, doctor or pharmacist. paroxetine, sertraline; SNaRIs e.g. venlafaxine; - This medicine has been prescribed for you only. tricyclic and tetracyclic antidepressants e.g. Do not pass it on to others. It may harm them, amitriptyline, dothiepin, maprotiline even if their signs of illness are the same as yours. - diuretics, also known as ‘water tablets’, e.g. - If you get any side effects, talk to your doctor bendroflumethiazide, furosemide or pharmacist. This includes any possible side - anaesthetics, used for the temporary loss of effects not listed in this leaflet. See section 4. bodily sensation - antihistamines e.g. terfenadine What is in this leaflet - medicines for other mental health conditions 1. What Clomipramine is and what it is used for. such as schizophrenia or manic depression 2.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Medications to Avoid in Long QT Syndrome
    Jackie Crawford Cardiac Inherited Disease Co-ordinator C/- Paediatric Cardiology; Level 3 Starship; Auckland City Hospital Private Bag 92024; Auckland Cardiac Inherited Disease Registry Phone: (09) 3074949 ext 23634 www.cidg.org Fax: (09) 6309877 Email: [email protected] Medications to be avoided, or requiring special caution, in people with Long QT syndrome This list includes medications which prolong the QT interval and is meant as a guide for people with Long QT syndrome, or acquired long QT interval from heart muscle disease, and their parents or guardians. It should not be seen as all inclusive. Those prescribing any medication to someone with Long QT syndrome should always check the drug specifications and contra-indications. The list has been compiled by review of publications and/or drug advice sheets provided with medications. Check also www.SADS.org and www.Torsades .org. Antibiotics Erythromycin, Clarithromycin, Gatifloxacin, levofloxacin, Moxifloxacin Sulfamethoxazole-trimethoprim (Septrin/Bactrim), Spiramycin, Pentamidine Antihistamines Terfenadine, Astemizole, Diphenhydramine, (These are particularly to be avoided (even in normal subjects) in combination with Erythromycin or grapefruit juice or the antifungals ketoconazole, miconazole, fluconazole or itraconazole) [Antihistamines that may be used safely are loratidine, cetirizine and fexofenadine, and phenergan] Appetite suppressants Fenfluramine, phentermine, Sibutramine Asthma treatments The Beta-2 agonists (e.g. Terbutaline, Salbutamol, Salmeterol) both work against
    [Show full text]
  • Medicines That Adversely Affect Allergy Skin Testing
    1 OSU Department of Otolaryngology–Head and Neck Surgery Division of Sinus and Allergy at the OSU Eye and Ear Institute 915 Olentangy River Rd. 4th Floor Columbus, Oh 43212 614-366-ENTS (3687) Medicines that affect allergy skin testing: Do not take these medications 5 days or longer (as listed below), prior to your appointment: *This is not an all-inclusive list, review all the ingredients on the package or ask your doctor or pharmacist.* Antihistamines - First Generation Generic Name Brand Names Azatadine Optimine Bromphenarimine BroveX, Dimetane, Lodrane Carbinoxamine Maleate Histex Pd, Palgic and Pediatex AHIST, Aller-Chlor, C.P.M, Chlo-Amine, Chlor-Allergy, Chlor-Mal, ChlorTrimeton, Chlorphen, Chlorpheniramine (6 days) Effidac-24, Histex, Ridraman Clemastine (10 days) Allerhist-1, Contact 12hr Allergy, Tavist-1 Cyproheptadine (11 days) Periactin Dexchlorpheniramine Polaramine Actifed Sinus Day, Aler-Tab, Allergy, AllergySinus, Allermax, Aler-Dryl, Altaryl, Banophren, Benadryl, Calm-Aid, Children's Allergy, Compoz Nighttime, Diphedryl, Diphen-Allergy, Diphenhist, Dormin Sleep Aide, Dytan, Dytuss, Genahist, Hydramine, Ibuprofen PM, Nu-Med, Nytol, PediaCare Diphenhydramine Children's Allergy, Q-Dryl, Quenalin, Scot-Tussin Allergy, Siladryl, Silphen, Simply Allergy, Simply Sleep, Sleep-ettes, Sleep Formula, Sleepinal, Sominex, Tavist, Theraflu, Triaminic, Twilite, Tylenol PM, Unisom Sleep Gels, Valu-Dryl Dimenhydrinate Dramamine Hydroxyzine (8 days) Atarax, Rezine, Vistaril Ketotifen Zatiden Meclizine HCl Antivert, Bonine Methdilazine
    [Show full text]
  • Cytochrome P450 Drug Interaction Table
    SUBSTRATES 1A2 2B6 2C8 2C9 2C19 2D6 2E1 3A4,5,7 amitriptyline bupropion paclitaxel NSAIDs: Proton Pump Beta Blockers: Anesthetics: Macrolide antibiotics: caffeine cyclophosphamide torsemide diclofenac Inhibitors: carvedilol enflurane clarithromycin clomipramine efavirenz amodiaquine ibuprofen lansoprazole S-metoprolol halothane erythromycin (not clozapine ifosfamide cerivastatin lornoxicam omeprazole propafenone isoflurane 3A5) cyclobenzaprine methadone repaglinide meloxicam pantoprazole timolol methoxyflurane NOT azithromycin estradiol S-naproxen_Nor rabeprazole sevoflurane telithromycin fluvoxamine piroxicam Antidepressants: haloperidol suprofen Anti-epileptics: amitriptyline acetaminophen Anti-arrhythmics: imipramine N-DeMe diazepam Nor clomipramine NAPQI quinidine 3OH (not mexilletine Oral Hypoglycemic phenytoin(O) desipramine aniline2 3A5) naproxen Agents: S-mephenytoin imipramine benzene olanzapine tolbutamide phenobarbitone paroxetine chlorzoxazone Benzodiazepines: ondansetron glipizide ethanol alprazolam phenacetin_ amitriptyline Antipsychotics: N,N-dimethyl diazepam 3OH acetaminophen NAPQI Angiotensin II carisoprodol haloperidol formamide midazolam propranolol Blockers: citalopram perphenazine theophylline triazolam riluzole losartan chloramphenicol risperidone 9OH 8-OH ropivacaine irbesartan clomipramine thioridazine Immune Modulators: tacrine cyclophosphamide zuclopenthixol cyclosporine theophylline Sulfonylureas: hexobarbital tacrolimus (FK506) tizanidine glyburide imipramine N-DeME alprenolol verapamil glibenclamide indomethacin
    [Show full text]
  • Pediatric Pharmacotherapy
    Pediatric Pharmacotherapy A Monthly Review for Health Care Professionals of the Children's Medical Center Volume 1, Number 9, September 1995 ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS IN CHILDREN • Overview • First Generation Antihistamines o Oral Dosing, Product Examples o Drug Interactions • Second Generation Antihistamines o Oral Dosing, Product Examples o Drug Interactions • Costs of Commonly Prescribed Preparati ons • Product Selection • References FDA News Pharmacology Literature Reviews • Leading Pharmaceuticals • Drug Induced Skin Reactions • Etoposide Pharmacokinetics and Pharmacodynamics • Macrolide Drug Interactions • New Theophylline Guidelines • Ticarcillin/Clavulinic Acid Dosing Formulary Update ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS IN CHILDREN It has been estimated that more than 10% of school -age children have seasonal allergic rhinitis. Although considered a relatively minor illness by many health care professionals, allergic reactions can result in missed school days, poor school performance, and impaired function on standardized tests (1). The management of allergic rhinitis consists primarily of the administration of H1 -receptor antagonists (antihistamines). There is a wide array of products marketed in the United States, including both products which are available over -the-counter (OTC) and those which require a prescription(2 -6). This brief rev iew is designed to provide basic information regarding the selection and monitoring of antihistamines in children. First -generation Antihistamines These agents were the first H1 -receptor antagonists available. They have been marketed in the United States since the 1950's. Many of the products within this group are available without a prescription. These agents are very effective, although they cause varying degrees of drowsiness which limits their usefulness. There are five major classes of first -generatio n antihistamines: alkylamines, ethanolamines, ethylenediamines, piperazines, and phenothiazines.
    [Show full text]